HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Hemolytic uremic syndrome — Clinical Guidelines

Overview

Hemolytic uremic syndrome (HUS) is a heterogeneous group of disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, with etiologies ranging from Shiga toxin-producing Escherichia coli (STEC) infections to complement dysregulation 1 7.

Diagnosis

Clinical Presentation: Microangiopathic hemolysis (schistocytes on peripheral smear), thrombocytopenia, and acute kidney injury 1 2 6.

Laboratory Tests: Complete blood count, peripheral blood smear, serum creatinine, blood urea nitrogen (BUN), and complement profile (C3, C4, factor H, MCP) 1 3 5.

Imaging: Renal ultrasound showing hyperechogenic renal cortex and sonolucent pyramids 18.

Etiologic Evaluation: Stool cultures for STEC, serologic tests for anti-factor H antibodies, genetic testing for complement mutations 1 3 5 8.

Management

First-Line Treatments:

- Supportive Care: Fluid resuscitation, blood transfusion, and dialysis for acute kidney injury 1 2 10. - Plasma Exchange: Recommended for severe cases to remove circulating toxins and restore complement function 2 11.

Adjunctive Treatments:

- Eculizumab: For complement-mediated HUS (aHUS), eculizumab is effective but access varies by region 1 3 4. - Control of Underlying Causes: Address hypertension, manage infections, and treat underlying conditions like cobalamin deficiency 5 8.

Special Populations

Pediatrics: HUS is a significant cause of acute kidney injury in children, often post-diarrheal; early diagnosis and supportive care are crucial 2 3 10.

Pregnancy: Postpartum HUS can occur in patients with preexisting hypertension or preeclampsia; early recognition and management are vital for outcomes 9.

Comorbidities: Hypertensive emergency can mimic aHUS and complicate management; careful monitoring and control of blood pressure are essential 5.

Key Recommendations

Early Diagnosis and Supportive Care: Initiate supportive measures including dialysis and plasma exchange for severe cases to improve outcomes (Evidence: Strong 2 10).

Use of Eculizumab: Consider eculizumab for patients with complement-mediated HUS (aHUS) to target the underlying pathophysiology (Evidence: Moderate 1 3).

Comprehensive Etiologic Evaluation: Perform thorough diagnostic workup including stool cultures, complement assays, and genetic testing to identify specific causes (Evidence: Moderate 1 3 5).

Tailored Management Based on Etiology: Adjust treatment strategies based on identified etiology, such as managing hypertension or treating infections (Evidence: Moderate 5 8).

Close Monitoring in Special Populations: Pay particular attention to pediatric and postpartum patients due to higher morbidity and mortality risks (Evidence: Expert opinion 2 9).

References

1 Kavanagh D, Ardissino G, Brocklebank V, Bouwmeester RN, Bagga A, Ter Heine R et al.. Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum. Kidney international 2024. link 2 Vilardouro AS, Cachão J, Rodrigues M, Durão F, Costa-Reis P, Sandes AR et al.. Hemolytic-uremic syndrome: 24 years' experience of a pediatric nephrology unit. Jornal brasileiro de nefrologia 2023. link 3 Khandelwal P, Bagga A. Guidelines on Hemolytic Uremic Syndrome by Indian Society of Pediatric Nephrology: Key Messages. Indian pediatrics 2020. link 4 Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J et al.. Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatric nephrology (Berlin, Germany) 2019. link 5 El Karoui K, Boudhabhay I, Petitprez F, Vieira-Martins P, Fakhouri F, Zuber J et al.. Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica 2019. link 6 Oualha M, Pierrepont S, Krug P, Gitiaux C, Hubert P, Lesage F et al.. Postdiarrheal hemolytic and uremic syndrome with severe multiorgan involvement and associated early risk factors. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2018. link 7 Wijnsma KL, Schijvens AM, Rossen JWA, Kooistra-Smid AMDM, Schreuder MF, van de Kar NCAJ. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2. Pediatric nephrology (Berlin, Germany) 2017. link 8 Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF et al.. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. American journal of kidney diseases : the official journal of the National Kidney Foundation 2014. link 9 Karam JS, Pitiranggon P, Wheat H, Stefanick B, Venuto RC. Postpartum hemolytic uremic syndrome in a patient with preexisting hypertension and resolving preeclampsia. Clinical nephrology 2007. link 10 Mate-Kole M, Lartey M. Hemolytic uremic syndrome: a case report from Africa. Renal failure 2003. link 11 Jiang M, Saigo K, Kumagai S, Imoto S, Kosaka Y, Matsumoto H et al.. Quantification of red blood cell fragmentation by automated haematology analyser XE-2100. Clinical and laboratory haematology 2001. link 12 Sebbag H, Lemelle JL, Moller C, Schmitt M. Colonic stenosis after hemolytic-uremic syndrome. European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie 1999. link 13 Vierzig A, Roth B, Querfeld U, Michalk D. A 12-year-old boy with fatal hemolytic-uremic-syndrome, excessive neutrophilia and elevated endogenous granulocyte-colony-stimulating-factor serum concentrations. Clinical nephrology 1998. link 14 Agarwal A, Mauer SM, Matas AJ, Nath KA. Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: current concepts and management. Journal of the American Society of Nephrology : JASN 1995. link 15 Rothman D, Gulli V. Colonic necrosis in the hemolytic uremic syndrome. New Jersey medicine : the journal of the Medical Society of New Jersey 1991. link 16 Geller M. Multisystem failure in a child with HUS. Critical care nurse 1990. link 17 Goodlin R, Mostello D. Maternal hyponatremia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. American journal of obstetrics and gynecology 1987. link90351-6) 18 Kenney PJ, Brinsko RE, Patel DV, Spitzer RE, Farrar FM. Sonography of the kidneys in hemolytic uremic syndrome. Investigative radiology 1986. link 19 Hanvanich M, Moollaor P, Suwangool P, Sitprija V. Hemolytic uremic syndrome in leptospirosis bataviae. Nephron 1985. link 20 Sun CC, Hill JL, Combs JW. Hemolytic-uremic syndrome: initial presentation mimicking intestinal intussusception. Pediatric pathology 1983. link 21 Talbert RL, Wong YY, Duncan DB. Propranolol plasma concentrations and plasmapheresis. Drug intelligence & clinical pharmacy 1981. link 22 DiBartolomeo A, Parker DL. Transplantation in the hemolytic-uremic syndrome. Urology 1975. link90596-8)

Hemolytic uremic syndrome